An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced. It is the first FDA-approved treatment for COPD in more than two ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...

The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, is the world’s preeminent COPD research and advocacy organization. Founded in 1997 in collaboration with the U.S. National ...

A new study finds that a sensor-equipped "smart inhaler" can accurately track how—and how well—COPD patients use their medication at home, offering clinicians real-time insights into patient behavior ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...

Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status and ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...